Allogene Therapeutics, Inc. ALLO
1.65
(0.02)
(1.20%)
as of 25 Sep
- Market cap
- $594.2M
- P/E
- 0.0×
Follow ALLO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
250.21 | 292.48 | 448.70 | 517.32 | 457.30 | 827.91 | 530.53 | 459.38 | — |
Total current assets |
257.75 | 303.39 | 459.12 | 528.82 | 471.32 | 845.13 | 544.58 | 467.98 | — |
Property, Plant, Equpment (Net) |
72.84 | 86.06 | 99.48 | 112.84 | 122.99 | 118.84 | 56.45 | 8.60 | — |
Long-Term Investments |
8.04 | 80.67 | 3.65 | 76.47 | 382.38 | 207.95 | 63.21 | 261.97 | — |
Goodwill and Intangible Assets (Total) |
— | — | — | — | — | — | 0.15 | 0.75 | — |
Long-term assets (Other) |
37.39 | 33.39 | 16.90 | 19.86 | 16.11 | 14.62 | 8.92 | 1.54 | — |
Total non-current assets |
158.16 | 245.32 | 183.72 | 292.76 | 579.50 | 382.70 | 173.23 | 305.87 | — |
Total Assets |
415.91 | 548.71 | 642.84 | 821.58 | 1,050.83 | 1,227.83 | 717.80 | 773.86 | 0.00 |
Accounts Payable |
4.27 | 5.39 | 5.90 | 13.89 | 10.26 | 10.39 | 9.25 | 12.34 | — |
Accrued Expenses |
28.24 | 30.13 | 31.18 | 39.74 | 37.50 | 44.94 | 23.83 | 17.12 | 0.00 |
Current Revenue (Deferred) |
— | — | 0.09 | 0.10 | 0.16 | 38.99 | — | — | — |
Total current liabilities |
32.51 | 35.52 | 37.08 | 53.73 | 47.91 | 94.32 | 33.08 | 29.46 | 0.00 |
Non-current Liabilities (Other) |
15.80 | 7.76 | 5.18 | 5.85 | 7.79 | 3.08 | 4.35 | 6.78 | — |
Total non-current liabilities |
90.85 | 91.01 | 93.53 | 100.97 | 77.72 | 53.89 | 55.70 | 41.23 | — |
Total liabilities |
123.36 | 126.53 | 130.60 | 154.70 | 125.63 | 148.21 | 88.78 | 70.69 | 0.00 |
Additional Paid In Capital |
2,302.75 | 2,241.88 | 2,075.25 | 1,911.63 | 1,822.18 | 1,725.55 | 1,023.88 | 914.27 | — |
Common Stock (Net) |
0.23 | 0.21 | 0.17 | 0.14 | 0.14 | 0.14 | 0.12 | 0.12 | 0.03 |
Retained Earnings |
(2,010.71) | (1,819.82) | (1,562.23) | (1,234.97) | (894.55) | (646.34) | (396.12) | (211.53) | (0.02) |
Shareholders Equity (Other) |
— | — | — | — | — | — | — | — | 0.00 |
Common Equity (Total) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 629.02 | 703.16 | 0.00 |
Shareholders Equity (Total) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 629.02 | 703.16 | 0.00 |
Shareholders Equity and Liabilities (Total) |
415.91 | 548.71 | 642.84 | 821.58 | 1,050.83 | 1,227.83 | 717.80 | 773.86 | — |
Shares (Common) |
229.41 | 212.21 | 168.64 | 144.44 | 142.62 | 140.47 | 124.27 | 121.48 | 26.25 |
Shareholders Equity (Tangible) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 628.87 | 702.41 | 0.00 |
Net Debt |
(250.21) | (292.48) | (448.70) | (517.32) | (457.30) | (827.91) | (530.53) | (459.38) | — |
Total Debt |
— | — | — | 101.00 | 73.00 | 54.00 | 51.00 | 34.00 | — |
In millions of $ except per-share values · columns are period end dates